Make Epidiolex available on prescription for childhood Epilepsy

Rejected 21 signatures

What the petition asks

Epidiolex is a CBD (Cannabidiol) based drug produced by GW Pharmaceuticals in the UK for treating childhood epilepsy that has completed its 3rd stage trials and is just about to be prescribed for the first time in pharmacies in Denver Colorado in the USA

GW’s Epidiolex®

Epidiolex is GW’s lead cannabinoid product candidate and is a proprietary oral solution of pure plant-derived cannabidiol, or CBD. GW’s Epidiolex development is initially concentrating on severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS).

Why it was rejected

It asked for something that is not the responsibility of the UK Government or Parliament.

We can only accept petitions about matters that the UK Government or the House of Commons are responsible for.

The UK Government and Parliament don't licence medicines or advise doctors on what to prescribe.

The European Medicines Agency and the Medicines and Healthcare products Regulatory Agency are responsible for licensing medicines.

The pharmaceutical company applied to EMA for a licence in February 2018.

You can find out more about unlicensed medicines and prescriptions here:

https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/prescribing-and-managing-medicines-and-devices/prescribing-unlicensed-medicines

Timeline

29 Mar 2018	Petition opened for signatures
19 Apr 2018	Rejected by the Petitions Committee

Key facts

Signatures 21

Status Rejected

Rejected 19 Apr 2018

Follow this petition